CAS: 1639810-67-5

Longiferone B shows anti-inflammatory activity against NO release with IC50 values of 21.0 uM, it also suppresses the iNOS and COX-2 mRNA expression.

Longiferone B is a bioactive phytochemical compound, which is derived from the plant species of the genus Eurycoma, known for its ethnomedicinal applications. Its mode of action involves the modulation of cellular pathways that regulate cell proliferation and apoptosis, providing potential therapeutic benefits in oncology research. Specifically, Longiferone B has been shown to interfere with various signaling mechanisms that tumors exploit for growth and spread, indicating its potential as an anti-cancer agent. In scientific studies, Longiferone B has been explored for its potential applications in treating various types of cancer, given its ability to selectively target malignant cells while sparing normal cells. This specificity may reduce the side effects typically associated with conventional chemotherapeutic agents. Additionally, its natural origin offers an advantage in biocompatibility and reduced toxicity. Overall, ongoing research is essential to further understand its mechanisms and optimize its efficacy and safety profile for clinical applications.